Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$412.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$411.43M
Gross Margin
20.56%
TTM Avg
22.27%
3Y Avg
19.63%
5Y Avg
19.86%
Market Cap
$409.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$417.78M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
Market Cap
$419.18M
Gross Margin
100.00%
TTM Avg
-208.30%
3Y Avg
-64.13%
5Y Avg
-41.74%
Market Cap
$417.94M
Gross Margin
44.71%
TTM Avg
23.54%
3Y Avg
19.38%
5Y Avg
-46.55%
Market Cap
$405.74M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$403.77M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $412.91M | 0.00% | 0.00% | 0.00% | N/A |
| Rezolute, Inc. (RZLT)vs › | $409.39M | 0.00% | 0.00% | 0.00% | 0.00% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.43M | 20.56% | 22.27% | 19.63% | 19.86% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $409.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prothena Corporation plc (PRTA)vs › | $417.78M | 61.77% | 80.89% | 90.44% | -1369.52% |
| Editas Medicine, Inc. (EDIT)vs › | $419.18M | 100.00% | -208.30% | -64.13% | -41.74% |
| Senseonics Holdings, Inc. (SENS)vs › | $417.94M | 44.71% | 23.54% | 19.38% | -46.55% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | 0.00% | 0.00% | 0.00% | 12.37% |
| Myriad Genetics, Inc. (MYGN)vs › | $403.77M | 68.83% | 69.91% | 69.67% | 69.68% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $423.41M | 73.89% | 76.35% | -237.05% | -138.49% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-03-31 | 0.00% |
